{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:58Z","timestamp":1790769358031,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":15,"publisher":"Springer US","isbn-type":[{"value":"9781071654750","type":"print"},{"value":"9781071654767","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5476-7_16","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:33:49Z","timestamp":1790764429000},"page":"243-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gapmer and Mixmer Antisense Oligonucleotides to Selectively Suppress the Mutant Allele in COL6A Genes in Dominant Ullrich Congenital Muscular Dystrophy"],"prefix":"10.1007","author":[{"given":"Sara","family":"Aguti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Marrosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"16_CR1","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.3390\/pharmaceutics14112389","volume":"14","author":"M Amanat","year":"2022","unstructured":"Amanat M et al (2022) Antisense oligonucleotide therapy for the nervous system: from bench to bedside with emphasis on paediatric neurology. Pharmaceutics 14:2389","journal-title":"Pharmaceutics"},{"key":"16_CR2","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1016\/j.ymthe.2025.04.038","volume":"33","author":"Lat Torres-Masjoan","year":"2025","unstructured":"Torres-Masjoan Lat (2025) Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases. Mol Ther 33:2689\u20132704","journal-title":"Mol Ther"},{"key":"16_CR3","doi-asserted-by":"publisher","first-page":"1414658","DOI":"10.3389\/fnins.2024.1414658","volume":"18","author":"S McDowall","year":"2024","unstructured":"McDowall S et al (2024) Antisense oligonucleotides and their applications in rare neurological diseases. Front Neurosci 18:1414658","journal-title":"Front Neurosci"},{"key":"16_CR4","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1111\/j.1742-4658.2009.06908.x","volume":"276","author":"S Cerritelli","year":"2009","unstructured":"Cerritelli S et al (2009) Ribonuclease H: the enzymes in Eukaryotes. FEBS J 276:1494\u20131505","journal-title":"FEBS J"},{"key":"16_CR5","doi-asserted-by":"publisher","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","volume":"268","author":"BP Moniass","year":"1993","unstructured":"Moniass BP et al (1993) Evaluation of 2\u2032 modified oligonucleotides containing 2\u2032 -deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268:14514\u201314522","journal-title":"J Biol Chem"},{"key":"16_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS et al (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46\u201351","journal-title":"Adv Drug Deliv Rev"},{"key":"16_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22\u201331","journal-title":"N Engl J Med"},{"key":"16_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2402478","volume":"391","author":"MA Riedl","year":"2024","unstructured":"Riedl MA et al (2024) Efficacy and safety of Donidalorsen for hereditary angioedema. N Engl J Med 391:21\u201331","journal-title":"N Engl J Med"},{"key":"16_CR9","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1080\/14656566.2024.2408369","volume":"25","author":"AJ Hooper","year":"2024","unstructured":"Hooper AJ et al (2024) Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia. Expert Opin Pharmacother 25:1861\u20131866","journal-title":"Expert Opin Pharmacother"},{"key":"16_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.omtn.2017.07.006","volume":"8","author":"E Marrosu","year":"2017","unstructured":"Marrosu E et al (2017) Gapmer antisense oligonucleotides suppress the mutant allele of col6a3 and restore functional protein in Ullrich muscular dystrophy. Mol Ther Nucleic Acids 8:416\u2013427","journal-title":"Mol Ther Nucleic Acids"},{"key":"16_CR11","doi-asserted-by":"publisher","first-page":"102237","DOI":"10.1016\/j.omtn.2024.102237","volume":"35","author":"S Aguti","year":"2024","unstructured":"Aguti S et al (2024) Strategies to improve the design of gapmer antisense oligonucleotide on allele-specific silencing. Mol Ther Nucleic Acids 35:102237","journal-title":"Mol Ther Nucleic Acids"},{"key":"16_CR12","first-page":"3525","volume":"128","author":"M Cescon","year":"2015","unstructured":"Cescon M et al (2015) Collagen VI at a glance. J Cell Sci 128:3525\u20133531","journal-title":"J Cell Sci"},{"key":"16_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.22283","volume":"69","author":"AR Foley","year":"2011","unstructured":"Foley AR et al (2011) Large genomic deletions: a novel cause of Ullrich congenital muscular dystrophy. Ann Neurol 69:206\u2013211","journal-title":"Ann Neurol"},{"key":"16_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/ana.22087","volume":"68","author":"L Bri\u00f1as","year":"2010","unstructured":"Bri\u00f1as L et al (2010) Early onset collagen VI myopathies: genetic and clinical correlations. Ann Neurol 68:511\u2013520","journal-title":"Ann Neurol"},{"key":"16_CR15","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1212\/01.wnl.0000307749.66438.6d","volume":"70","author":"D Hicks","year":"2008","unstructured":"Hicks D et al (2008) A refined diagnostic algorithm for Bethlem myopathy. Neurology 70:1192\u20131199","journal-title":"Neurology"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5476-7_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:02:34Z","timestamp":1790766154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5476-7_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654750","9781071654767"],"references-count":15,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5476-7_16","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}